FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Stock Information for Lipocine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lipocine Inc.

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
Lipocine Announces FDA Labeling Changes for Testosterone Products

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.